Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex^® Outcomes

References

• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539
   PubMed Web of Science ®Google Scholar
• Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.
   PubMed Web of Science ®Google Scholar
• Al Dhibi HA, Arevalo JF. Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes. 2013;4(6):295–302. doi:10.4239/wjd.v4.i6.295
   Google Scholar
• Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686–694. doi:10.1016/j.ajo.2011.03.033
   PubMed Web of Science ®Google Scholar
• Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122(12):1801–1807. doi:10.1001/archopht.122.12.1801
   Google Scholar
• Ozurdex®. Summary of product characteristics. Available from: https://www.ema.europa.eu/medicines/human/EPAR/ozurdex. Accessed August 18, 2021.
   Google Scholar
• Iluvien®. Summary of product characteristics; 2019. Available from: https://www.medicines.org.uk/emc/product/3061/smpc. Accessed August 18, 2021.
   Google Scholar
• Escobar-Barranco JJ, Pina-Marin B, Fernandez-Bonet M. Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema. Ophthalmologica. 2015;233(3–4):176–185. doi:10.1159/000371770
   PubMed Web of Science ®Google Scholar
• Guigou S, Pommier S, Meyer F, et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica. 2015;233(3–4):169–175. doi:10.1159/000381356
   PubMed Web of Science ®Google Scholar
• Chhablani J, Bansal P, Veritti D, et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye. 2016;30(3):426–430. doi:10.1038/eye.2015.246
   PubMed Web of Science ®Google Scholar
• Malclès A, Dot C, Voirin N, et al. Real-life study in diabetic macular edema treated with Dexamethasone implant: the Reldex study. Retina. 2017;37(4):753–760. doi:10.1097/IAE.0000000000001234
   PubMed Web of Science ®Google Scholar
• Pareja-Ríos A, Ruiz-de la Fuente-Rodríguez P, Bonaque-González S, López-Gálvez M, Lozano-López V, Romero-Aroca P. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol. 2018;11(1):77–82.
   PubMed Web of Science ®Google Scholar
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group Real-Life 24-month multicenter study. The IRGREL-DEX study. Retina. 2018;39(1):44–51. doi:10.1097/IAE.0000000000002196
   Web of Science ®Google Scholar
• Nagpal M, Mehrotra N, Juneja R, Jain H. Dexamethasone implant (0.7 mg) in Indian patients with macular edema: real-life scenario. Taiwan J Ophthalmol. 2018;8(3):141–148. doi:10.4103/tjo.tjo_62_17
   Google Scholar
• Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernández-Bel L, Montero-Hernández J. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1):15. doi:10.1186/s12886-018-1022-9
   PubMed Web of Science ®Google Scholar
• Rosenblatt A, Udaondo P, Cunha-Vaz J, et al.; ARTES Study Group. A collaborative retrospective study on the efficacy and safety of intravitreal Dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME registry study. Ophthalmology. 2020;127(3):377–393. doi:10.1016/j.ophtha.2019.10.005.
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with Dexamethasone implant. Ophthalmology. 2018;125(2):267–275. doi:10.1016/j.ophtha.2017.08.031
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Zarranz-Ventura J, Valverde A, et al. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study. Graefes Arch Clin Exp Ophthalmol. 2019;257(11):2381–2390. doi:10.1007/s00417-019-04446-4
   PubMed Web of Science ®Google Scholar
• Eandi CM, De Geronimo D, Giannini D, et al. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants. Acta Diabetol. 2020;57(7):867–874. doi:10.1007/s00592-020-01504-w
   Web of Science ®Google Scholar
• Udaondo P, Adan A, Arias-Barquet L, et al. Challenges in diabetic macular edema management: an expert consensus report. Clin Ophthalmol. 2021;15:3183–3195. doi:10.2147/OPTH.S320948
   Web of Science ®Google Scholar
• Bullimore MA, Bailey IL, Friend J, McCarthy D, Wu SY. The lens opacities classification system III. The longitudinal study of Cataract Study Group. Arch Ophthalmol. 1993;111(6):831–836. doi:10.1001/archopht.1993.01090060119035
   Google Scholar
• Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018;2018:8289253. doi:10.1155/2018/8289253
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 2018;138(4):219–232. doi:10.1016/j.jphs.2018.11.001
   PubMed Web of Science ®Google Scholar
• Bahadorani S, Krambeer C, Wannamaker K, et al. The effects of repeated Ozurdex injections on ocular hypertension. Clin Ophthalmol. 2018;12:639–642. doi:10.2147/OPTH.S148990
   PubMed Web of Science ®Google Scholar
• Hemarat K, Kemmer JD, Porco TC, Eaton AM, Khurana RN, Stewart JM. Secondary ocular hypertension and the risk of glaucoma surgery after Dexamethasone intravitreal implant in routine clinical practice. Ophthalmic Surg Lasers Imaging Retina. 2018;49(9):680–685. doi:10.3928/23258160-20180831-05
   Web of Science ®Google Scholar
• Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, Montero-Hernández J, Cervera-Taulet E. Effect of Dexamethasone intravitreal implant on visual acuity and foveal photoreceptor integrity in macular edema secondary to retinal vascular disease. Ophthalmologica. 2021;244(1):83–92.
   Web of Science ®Google Scholar